|
The 21st International Prostate Cancer Update
Wednesday, January 26, 2011 - Saturday, January 29, 2011
Cascade Conference Center
Vail, Colorado
Click on the Presentations to Download PDFs
Thursday, January 27
|
SESSION I: BASIC SCIENCE
Chair: Alan W. Partin, MD, PhD
|
Welcome and Introduction
E. David Crawford, MD |
Promising New Biomarkers for Prostate Cancer
M. Scott Lucia, MD |
Androgen Receptor Overexpression: Beyond PCA Testing
Daniel P. Petrylak, MD |
From Genomics to New Therapeutic Approaches: Dissecting and Understanding Prostate Cancer Biology
Timothy C. Thompson, PhD
|
SESSION II: PREVENTION/SCREENING
Chair: Neal D. Shore, MD
|
Screening for Prostate Cancer: Why the Controversy?
Leonard G. Gomella, MD |
Mens Health from the Urologists Viewpoint: The International Approach
Frans M.J. Debruyne, MD, PhD |
PSA Screening and Expectant Management
Alan W. Partin, MD, PhD |
How Well is My Patient Doing? Use of Symptom Scales and Questionnaires in Clinical and Research Settings
Raymond C. Rosen, PhD |
Friday, January 28
|
SESSION III: LOCALIZED DISEASE
Chair: James A. Eastham, MD
|
Advances in Localized Treatment:
Myths and Realities of the Introduction of Technology and Use of Robotics in the Treatment of Prostate Cancer
Karim A. Touijer, MD |
Targeted Therapy Approaches: Cryosurgery, HIFU, IRE
Hashim U. Ahmed, MRCS (Ed), BM, BCh (Oxon), BA (Hons) |
Innovative Applications of New Technology in Imaging
James A. Eastham, MD |
Radiation Therapy: Myths and Reality
Nelson N. Stone, MD |
Debating the Role of Targeted Therapy: Pro | Con
Pro: Frans M.J. Debruyne, MD, PhD
Con: Nelson N. Stone, MD
|
SESSION IV: ADVANCED DISEASE AND HORMONE DEPRIVATION THERAPY
Chair: E. David Crawford, MD
|
Advances in HRT: Incorporating Hormones into Treatment
Defining Appropriate Testosterone Levels for Suppression
E. David Crawford, MD |
Uses of ADT in Neoadjuvant and Adjuvant Treatment in Radiation Therapy
Nelson N. Stone, MD |
Uses of ADT in Neoadjuvant and Adjuvant Treatment in Surgery
L. Michael Glodé, MD |
Bone Loss and the Role of RANK Ligand
Stephen J. Freedland, MD |
|
